Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT06168994
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT06168994
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06168994. Randomized; single masking; primary purpose prevention. Start 2024-02-01 (anticipated); primary completion 2026-09-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Drug)
- Eplerenone
- Lead sponsor
- Assiut University
Record details
- Record id
cardio:ct-nct06168994- Content hash
9149c8606aea342ea288575e4305f520aca2175737eead3340efb5163401dfc6